From Clinic to Lab: How Reverse Pharmacology Is Proving Ayurveda

Dr. Meera Iyer — Sat, 21 Feb 2026 06:00:00 +0000

Reverse pharmacology begins with a practical question: when a treatment has a documented history of human use, can that experience be converted into a disciplined research program? Instead of starting only with a molecular target and searching for a compound, investigators begin with a traditional remedy, formulation, procedure, or pattern of clinical use and then examine its identity, quality, dosage, safety, effectiveness, pharmacology, and possible mechanisms.

Ayurveda offers many such research leads because its literature and living clinical practice describe materia medica, compound formulations, diet, procedures, and individualized therapeutic reasoning. These records can generate hypotheses, but they are not substitutes for controlled evidence. Historical use may help researchers decide what to study first; it does not by itself establish efficacy, exclude toxicity, or guarantee that a modern commercial product matches the preparation described in an authoritative text.

Why the Starting Point Matters

Conventional drug development commonly proceeds through discovery and laboratory development, preclinical testing, phased clinical research, regulatory review, and post-market safety monitoring. This structure is essential for determining whether a medicine’s benefits outweigh its risks, yet attrition is high. A 2022 review estimated that about 90% of drug candidates entering phase I development do not ultimately obtain approval, with failures arising from factors such as inadequate efficacy, unacceptable toxicity, poor drug properties, and strategic or commercial decisions.

Reverse pharmacology changes the order of investigation, not the standard required at the end. A traditional-use lead may already provide information about how a preparation has been administered, the conditions for which it has been used, customary dose ranges, and cautions recognized by practitioners. Researchers must still authenticate every ingredient, define the manufacturing process, test batch consistency and contaminants, document adverse events, establish an appropriate comparator, and use prespecified outcomes and statistical methods.

This distinction is especially important in Ayurveda. The same vernacular name can be applied inconsistently, plant material can vary by species and geography, and compound medicines depend on the identity, proportion, processing, and quality of every ingredient. Preparations containing metals, minerals, or gems require particular attention to pharmaceutical standards, dose, duration, laboratory monitoring, and qualified supervision. Prior use is therefore a source of research direction, not a blanket safety certificate.

How Reverse Pharmacology Works in Ayurveda

A responsible program usually moves through connected stages. Investigators first define the traditional indication and the exact intervention being evaluated. They then establish raw-material identity, textual or formulary provenance, manufacturing controls, chemical or biological fingerprints where appropriate, stability, and contaminant limits. Observational work can refine eligibility criteria and identify possible benefits or adverse effects. Controlled trials test clinical outcomes, while laboratory and biomarker studies may explore pharmacokinetics, biological pathways, or responder subgroups. Results at one stage determine whether the next stage is justified.

Ayurvedic interventions also raise a design choice: should the trial test one isolated component or the therapeutic package as practiced? Both questions can be legitimate. A component trial can identify the contribution of a specific product, whereas a whole-system or multimodal trial can estimate the effect of a defined package that includes medicines and procedures. The research question must be stated clearly because a positive package trial does not reveal which component produced the effect, and a negative single-component trial does not necessarily evaluate the complete clinical approach.

A Registered Menorrhagia Protocol

PMID 40163851 corresponds to a genuine 2025 protocol in JMIR Research Protocols evaluating an Ayurvedic regimen for menorrhagia, correlated in the protocol with Raktapradara. The open-label randomized controlled trial was designed for 140 participants. The Ayurveda group receives Ashokarishta and Trinakantamani Pishti together with iron and folic acid, while the comparator group receives tranexamic acid with iron and folic acid. The primary assessment uses menstrual bleeding measures, including the Pictorial Blood Assessment Chart, and the protocol also includes the Menorrhagia Impact Questionnaire.

The protocol cites Ayurvedic and formulary sources for the selected preparations, specifies procurement from Good Manufacturing Practices-certified pharmacies with Certificates of Analysis, and records the trial in CTRI as CTRI/2023/05/052929. As of December 2024, the protocol reported 79 participants enrolled. It is a registered protocol rather than a published efficacy report, so its present value lies in its declared design, comparator, outcomes, sample plan, ethics oversight, and future accountability. The paper does not justify presenting the regimen as an established treatment result.

A Multimodal Knee Osteoarthritis Protocol

A separate 2025 JMIR Research Protocols paper, article e68306, describes an open-label randomized controlled noninferiority trial in 150 people with primary knee osteoarthritis at the All India Institute of Medical Sciences, New Delhi. Participants were assigned for 180 days to either a multimodal Ayurveda protocol or standard care with topical diclofenac sodium gel. The Ayurveda package includes Matra Basti with Ksheerabala Taila, Janu Basti with Dhanwantara Taila, and the oral preparations Laksha Guggulu and Muktashukti Bhasma.

The trial’s primary outcome is change in the WOMAC score. Secondary measures include pain, stiffness, physical function, knee range of motion, disability, quality of life, rescue-analgesic use, inflammatory markers, MRI findings, and bone mineral density. Adverse events, liver function, and kidney function are also monitored. The paper cites the Ayurvedic Pharmacopoeia of India for Ksheerabala Taila, Dhanwantara Taila, and Laksha Guggulu. This design evaluates a defined therapeutic package as a package; interpretation must therefore remain at that level unless later analyses separately test its components.

The Indian Ethical and Registration Framework

The Government of India published the Good Clinical Practice Guidelines for Clinical Trials in Ayurveda, Siddha and Unani Medicine, commonly called GCP-ASU, in 2013. The guidelines cover the design, conduct, termination, audit, analysis, reporting, and documentation of studies involving human participants. Their stated purposes include scientifically and ethically sound research, protection of participants’ rights, and generation of authentic clinical-trial data. A 2016 parliamentary answer clarified that GCP-ASU was a guiding tool rather than a legally binding instrument, while advising stakeholders to follow it.

The Indian Council of Medical Research’s 2017 National Ethical Guidelines for Biomedical and Health Research Involving Human Participants contains a dedicated section on clinical trials involving traditional systems of medicine. Government statements describing that section emphasize ethics review, serious and other adverse-event reporting, compensation, compliance with AYUSH GCP, and observance of other applicable regulations. These requirements matter whether an intervention is classical, proprietary, plant-based, mineral-based, procedural, or individualized.

The Clinical Trials Registry-India provides a public record of trial protocols. Government guidance has repeatedly advised registration of Ayurveda and other traditional-medicine trials, and the two protocols above provide CTRI identifiers. Prospective registration makes planned eligibility criteria, interventions, comparators, and outcomes visible before results are known. It improves transparency, but registration alone does not guarantee adequate randomization, blinding, adherence, complete reporting, or valid conclusions; those features must be assessed in the protocol and final publication.

Prakriti, Dosha, and Biomarker-Oriented Research

PMID 27473604 is also genuine, but the original attribution to Aggarwal and colleagues is incorrect. The study was led by Kalpana S. Joshi and colleagues and published in the Journal of Ethnopharmacology. It examined a whole-system, dosha-phenotype-specific Ayurveda intervention in people with mild to moderate bronchial asthma. The investigators assessed clinical symptoms, lung-function measures, immunoglobulin E, eosinophils, and circulating cytokines; 115 patients entered the study and 76 completed it, with a healthy comparison group used for cytokine measurements.

The design did not randomize participants to tailored versus non-tailored Ayurvedic care. It therefore supports investigation of relationships among Ayurvedic phenotype classification, clinical change, and immune measurements, but it does not isolate personalization itself as the cause of an outcome. A stronger test of that proposition would require a prespecified phenotype method, blinded outcome assessment, an appropriate comparison arm, adequate power, and replication in an independent population.

Genomic work has pursued a related question. A 2015 Scientific Reports study performed genome-wide single-nucleotide-polymorphism analysis in 262 well-classified male participants selected after screening 3,416 people across predominant Vata, Pitta, and Kapha Prakriti groups. The paper reported genetic differences associated with the classified groups. Such work treats Prakriti as a testable stratification hypothesis; it does not turn dosha categories into clinical genetic tests or replace Ayurvedic examination with a DNA result.

Procedure-Based Therapies Under Scrutiny

Ayurvedic procedure research is difficult but not methodologically impossible. Participants and therapists often cannot be blinded to enemas, oil-retention procedures, massage, or purgation, yet investigators can still use concealed allocation, blinded outcome assessors, standardized operating procedures, credible active comparators, validated scales, objective measures, predefined rescue treatment, adherence records, and systematic adverse-event monitoring. The knee osteoarthritis and Parkinson protocols illustrate several of these tools.

The systematic review indexed as PMC11705355 did not analyze 13 trials. It included 30 studies of Ayurvedic interventions for hemiplegia or Pakshaghata: nine randomized trials, eight nonrandomized comparative studies, and 13 pre-post studies. Methodological diversity and incompatible outcomes prevented quantitative meta-analysis. All but one study was judged to have substantial risk of bias, and weaknesses included missing protocols or registry records, limited masking, inconsistent outcomes, inadequate follow-up, and incomplete safety reporting.

The review therefore does not support a general claim that Basti, Nasya, or Panchakarma has demonstrated motor-recovery benefit alongside conventional stroke rehabilitation. Its useful contribution is a map of the existing literature and a clear research agenda: better randomization, transparent allocation, validated neurological and functional outcomes, adequate comparator care, longer follow-up, and explicit recording of adverse events and concomitant rehabilitation.

The NIMHANS Parkinson Disease Trial

PMID 41512294 refers to a 2026 protocol from the National Institute of Mental Health and Neurosciences in Bengaluru and collaborating CCRAS institutions. It is an assessor-blinded exploratory randomized controlled trial designed for 80 people with Parkinson disease. Participants continue optimized conventional treatment; one group additionally receives a defined 180-day Ayurvedic regimen. This is an add-on design, not a replacement for dopaminergic or other neurological management.

The primary outcome is change in the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale after six months. Secondary and exploratory assessments include motor and nonmotor measures, cognition, gait and balance, transcranial-magnetic-stimulation measures of cortical excitability, heart-rate variability, pulmonary function, immune-cell populations, inflammatory markers, cytokines, and telomere length. The protocol also specifies complete blood counts, liver and renal testing, adverse-event monitoring, and a blinded data analyst.

The Ayurvedic regimen includes preparatory treatment, a prespecified Yoga Basti schedule using decoction and oil enemas, and oral Mashabaladi Kwatha and Kalyanaka Ghrita in repeated cycles. As of August 2025, the protocol reported 58 participants enrolled, 33 completed, 14 discontinued, and 11 continuing, with completion scheduled for September 2026. These details describe an ongoing experiment; clinical or mechanistic conclusions must await completed analysis and publication of results.

What Rigorous Ayurveda Research Must Preserve

Good research should preserve the intervention’s identity without protecting it from falsification. For a classical formulation, investigators should document the authoritative reference used, ingredient identities, plant parts, processing steps, dosage form, dose, vehicle, duration, manufacturer, batch numbers, and quality-control results. For individualized treatment, the diagnostic rules and permissible treatment choices must be explicit enough for another qualified team to reproduce the process. For procedures, therapist training, materials, sequence, temperature, duration, and cointerventions should be standardized and recorded.

At the same time, modern trial safeguards remain essential. Randomization protects against systematic group differences; allocation concealment prevents foreknowledge of assignment; blinded assessment reduces measurement bias; validated outcomes make studies comparable; intention-to-treat analysis preserves the value of randomization; and adverse-event reporting prevents benefits from being discussed without harms. Pragmatic and whole-system trials can use these safeguards even when participant blinding is impossible.

Mechanistic work should follow rather than outrun credible clinical observations. Biomarkers can help with participant stratification, target engagement, safety assessment, dose selection, and explanation of response, but a change in a cytokine or gene-expression measure is not automatically a patient benefit. Conversely, a clinically meaningful result may justify later dismantling, pharmacology, or omics studies to identify active components and pathways. The most informative reverse-pharmacology program links these stages instead of treating any single experiment as final proof.

Where the Field Is Headed

The strongest future work in Ayurveda will combine textual accuracy, pharmaceutical quality, clinical relevance, and transparent modern methods. Traditional indications can prioritize questions; observational data can refine them; controlled trials can estimate benefits and harms; and pharmacology, metabolomics, genomics, and systems biology can investigate mechanisms or responder patterns. Each method answers a different question, and none should be asked to validate an entire medical system at once.

Reverse pharmacology is valuable precisely because it is neither automatic endorsement nor automatic dismissal. It treats documented traditional practice as a source of candidates and hypotheses, then applies progressively stricter tests. When a result is negative, the intervention, product, dose, population, or theory may need revision. When a result is positive, replication, safety surveillance, product standardization, and comparison with available care still remain.

For clinicians and researchers, the practical starting points are published protocols, CTRI records, final trial reports, pharmacopoeial or formulary standards, and systematic reviews that include risk-of-bias assessment. Reading these together helps distinguish a traditional rationale from a tested clinical effect, a registered plan from a completed result, and a biomarker hypothesis from a treatment recommendation.

Disclaimer: This article is for educational purposes and discusses registered, ongoing, and published research. Ayurvedic medicines and procedures should not be self-administered, especially products containing metals or minerals or treatments involving therapeutic enemas or purgation. Consult a qualified Ayurvedic practitioner and an appropriate medical healthcare provider for diagnosis, treatment, medication interactions, pregnancy, chronic illness, or any serious symptoms.

GCP-ASU – Ayurved Healing